XtalPi Partners with UCB to Accelerate Next-Gen Biologic Development via AI-Powered XtalFold™ Platform

Blog details
2 min read
Share this:

XtalPi (HKEX: 2228.HK) announced today that its biologics discovery division Ailux Biologics has entered into a strategic licensing agreement with Belgium-based global biopharmaceutical leader UCB (Euronext: UCB). Under the agreement, UCB gains access to XTALPI’s proprietary XtalFold™ AI platform for macromolecular drug discovery and engineering.

Platform Capabilities
The XtalFold™ suite enables rapid, high-accuracy structural modeling critical to biologic development stages including: 
– Antigen design & epitope mapping 
– Affinity maturation strategies 
– pH-sensitive modification 
– Bispecific antibody engineering 

Validated through rigorous benchmarking, XtalFold™ demonstrates industry-leading performance in modeling complex interactions at antibody-antigen interfaces – a persistent challenge in monoclonal antibody development. 

“UCB exemplifies how computational approaches can drive differentiated therapeutics. We’re honored to empower their R&D with AI-driven structural insights that accelerate life-changing discoveries.” 
Dr. Jian Ma, CEO of XtalPi Inc.

“Following the Nobel Prize recognition for protein structure prediction, XtalFold™ represents industrialized deployment of this breakthrough. As a fully validated solution, it’s becoming the new standard across biologics development.” 
Daniel Lightwood, Head of Antibody Discovery at UCB

“After exhaustive comparative testing, we’re confident XtalFold™ will enhance our ability to rapidly identify high-quality antibody candidates, ultimately delivering novel therapies to patients faster.” 
Dr. Alexander Hillisch, Global Head of CADD at UCB

Your next success starts here

Recommended articles

XtalPi Advances Global STEM Education Through AI-Powered Science Outreach
XtalPi Sweeps Prestigious Awards, Earning Global Recognition for AI Innovation
XtalPi Deploys AI Peptide Platform in Landmark Cancer Collaboration with Singapore Research Consortium
Dr. Ma Jian Honored with 2024 EY Entrepreneur Of The Year Award